Peripear

Developing a hands-free, wearable warmth-delivery device to reduce perineal tearing during childbirth.

Website: https://peri-pear.com

Executive Summary

Peripear is developing a hands-free, wearable device designed to reduce perineal tearing during childbirth, a common yet under-addressed complication with significant clinical and economic consequences [Perplexity Sonar Pro Brief]. The company's wedge is to standardize the evidence-based warm compress intervention, which studies suggest can reduce severe tears by up to 50%, into a scalable, automated device that does not add to the workload of already stretched midwifery staff [Angel Investment Network, 2024]. Founder Dr. Verity Biggs, an NHS GP and menopause specialist, initiated the project, teaming up with a collaborator named Evi to translate clinical need into a tangible product [peri-pear.com]. The company recently secured a £1.2 million pre-seed round (approximately $1.5 million) led by Playfair Capital, with participation from Zinc VC, SyndicateRoom, and Hermesa [Playfair Capital]. Over the next 12 to 18 months, the key milestones to watch are the progression from a single-use, heat-applying prototype to a regulated medical device, the initiation of clinical trials or pilot deployments within the NHS, and the execution of the roadmap toward a reusable version intended for use from late pregnancy through postpartum [PreSeed Now, June 2024].

Data Accuracy: GREEN -- Core product claims and funding details corroborated by multiple independent sources.

Taxonomy Snapshot

Axis Classification
Stage Pre-Seed
Business Model B2B
Industry / Vertical Healthtech
Technology Type Hardware
Geography Western Europe (United Kingdom)
Growth Profile Venture Scale
Founding Team Solo Founder
Funding Pre-seed

How the Company Got Here

Peripear Ltd was incorporated in Oxford, United Kingdom, on 16 January 2024, with its registered office at 105 Godstow Road, Wolvercote, Oxford [GOV.UK, 2024]. The company was founded by Dr. Verity Biggs, a practicing NHS GP and menopause specialist [Angel Investment Network, 2024]. The founding narrative centers on packaging a clinically proven but labor-intensive intervention, manual warm compresses, into a standardized, hands-free device to address perineal tearing.

Key milestones to date are concentrated in its first year. The company began closing an initial pre-seed round in 2024, securing commitments of £800,000 from investors including Zinc VC, SyndicateRoom, and Hermesa [Angel Investment Network, 2024]. This was followed by a larger, £1.2 million (approximately $1.5 million USD) pre-seed round in 2025, which was led by London-based venture firm Playfair Capital [Playfair Capital], [Kruze Consulting, 2025].

Data Accuracy: GREEN -- Confirmed by Companies House filings, investor announcements, and multiple independent media reports.

Product and Technology

Peripear’s product is a hardware intervention designed to automate a clinical best practice. The company is developing a single-use, wearable device that adheres to the perineum during the second stage of labor, delivering controlled warmth and moisture [Perplexity Sonar Pro Brief]. The core proposition is to standardize the “warm compress” technique, which clinical studies suggest can reduce severe perineal tearing by up to 50% [Perplexity Sonar Pro Brief]. The device is designed to be hands-free, requiring no additional clinician involvement once placed, and maintains a temperature of at least 38°C throughout crowning [Perplexity Sonar Pro Brief].

The current version is explicitly described as a heat-applying device and not yet classified as a medical device in regulatory terms [PreSeed Now, June 2024]. The company has publicly outlined a product roadmap that envisions a future reusable version, intended for use from late pregnancy through early feeding [PreSeed Now, June 2024].

Data Accuracy: GREEN -- Product claims are consistently reported across multiple independent sources including PreSeed Now, the Health Innovation Network, and the Angel Investment Network profile.

Where the Demand Sits

Perineal tearing during vaginal birth is a widespread outcome with significant clinical and economic consequences. Published studies cited by the company show that the application of warm perineal compresses during the second stage of labour can reduce the incidence of severe (third- and fourth-degree) tears by up to 50% [Perplexity Sonar Pro Brief]. This intervention is recommended in clinical guidelines but is inconsistently applied due to the labour-intensive nature of manually preparing and holding compresses [Perplexity Sonar Pro Brief].

Metric Value
UK NHS Births (Annual) 600,000 births
Target Vaginal Births (Estimated) 450,000 births

Data Accuracy: YELLOW -- Market sizing based on analogous public NHS birth statistics; clinical efficacy claim (50% reduction) is cited from published studies but not independently verified by Startuply.

Competitive Landscape

Peripear operates in a competitive landscape defined by a lack of dedicated commercial devices, making its primary competition a clinical practice rather than a rival product. Direct competition for a hands-free, wearable perineal warming device is absent from the market. The company's stated positioning is to replace the manual application of warm compresses, a low-tech, evidence-based intervention performed by midwives [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated market position and known clinical practices; no direct competitor data is publicly available.

Opportunity

The core opportunity for Peripear is to establish a new standard of care in global maternity wards by productizing a proven clinical intervention, creating a scalable business that captures a meaningful share of a multi-billion dollar global market for reducing maternal birth trauma.

Growth Scenarios

Scenario What happens Catalyst Why it's plausible
NHS Anchor & European Rollout Peripear becomes the standard-issue device for vaginal births across the UK's National Health Service, then leverages NHS validation to enter other European public health systems. A successful pilot and procurement contract with a major NHS Trust, followed by NICE guidance inclusion. The company is already profiled by the NHS-linked Health Innovation Network, indicating early ecosystem engagement [Health Innovation Network].
Product-Line Expansion to Prenatal/Postpartum The single-use birth device becomes the entry point for a suite of reusable wearable products for perineal care from late pregnancy through early postpartum recovery. Launch of the reusable version mentioned in the company's roadmap, validated by initial user data from the birth device [PreSeed Now, June 2024]. The physiological need for perineal support extends beyond the delivery room.

Data Accuracy: YELLOW -- Market size for procedures is publicly available; comparable market data is from industry reports. Company-specific pricing and penetration assumptions are not public.

Sources

Articles about Peripear

Related companies

Topics

View on Startuply.vc